【摘要】 目的探讨EB病毒BRLF1基因(EBV-BRLF1)表达量及血清EB病毒Rta/IgG(EBV-Rta/IgG)抗体浓度在鼻咽癌(NPC)早期诊断、临床分期中的意义。方法运用实时荧光定量聚合酶链反应法测量89例NPC组织的EBV-BRLF1基因表达量,采用EBV-Rta/IgG定量抗体试剂盒检测228例血清的Rta/IgG抗体浓度,分析它们与NPC早期诊断、临床分期的相关性。228例血清包括NPC组89例、鼻咽部慢性黏膜炎病例(高危组)19例和同期健康人群120例。结果 89例NPC组血清的EBV-Rta/IgG抗体浓度为(111.81±76.77)U/mL,灵敏度为75.3%(67/89),特异度为94.2%(131/139),诊断符合率为86.8%(198/228);19例高危组血清的EBV-Rta/IgG抗体浓度为(15.14±33.04)U/mL,120例健康体检组血清的EBV-Rta/IgG抗体浓度为(6.63±11.26)U/mL;各组间比较浓度差异具有统计学意义(P<0.05)。EBV-BRLF1基因在NPC肿瘤组织中的表达率为63.51%(47/74),中位表达量为8.53。NPC组中EBV-BRLF1基因表达量与N分期、M分期及临床分期无关(P>0.05),与T分期差异有关(P=0.061),接近临界范围。血清EBV-Rta/IgG抗体浓度与N分期、M分期及临床分期无关(P>0.05)。在T分期组间比较中发现,T3期呈一定上升趋势,T2与T3组间差异具有统计学意义(P=0.048)。结论 EBV-BRLF1基因在NPC组织中高度表达;EBV-Rta/IgG定量抗体试剂盒检测可以作为早期筛查NPC的临床指标之一;EBV-BRLF1基因表达量及血清EBV-Rta/IgG抗体浓度与NPC的N分期、M分期及临床分期无关,与T分期局部组织浸润呈一定相关性。更多还原

【Abstract】 Objective To explore the significance of Epstein-Barr virus BRLF1( EBV-BRLF1) gene expression and serum EBV-Rta / IgG antibody concentration on early diagnosis and clinical staging of nasopharyngeal carcinoma( NPC). Methods Real-time quantitative polymerase chain reaction( RT-Q-PCR) was used to measure the EBV-BRLF1 gene expression of 89 NPC tissues,and quantitative EBV-Rta / IgG antibody kit was used to detect the serum Rta / IgG antibody concentration of 228 clinical samples. The correlation between the NPC early diagnosis and clinical stages was analyzed. The serum samples included 89 NCP,19 cases with chronic nasophayngeal mucosal inflammation and 120 healthy people. Results The mean value of EBV-Rta / IgG concentration in 89 NPC patients was( 111. 81 ± 76. 77)U / mL,with a sensitivity of 75. 3%( 67 /89) and specificity of 94. 2%( 131 /139) and diagnosis coincidence rate of 86. 8%( 198 /228); The mean value of EBV-Rta / IgG concentration in 19 high risk group and 120 healthy volunteers were( 15. 14 ±33. 04) U/mL and( 6. 63 ± 11. 26) U/mL; There were significant difference between NPC and other groups( P <0. 05). EBV-BRLF1 gene expression rate in NPC tumor tissue was 63. 51%( 47/74),with median amount was8. 53. No significant difference in EBV-BRLF1 gene expression level was found in the NPC patients in different N,M or clinical stages( P > 0. 05) while the difference in T stage( P = 0. 061) was near to the critical range. No significant difference in EBV-Rta / IgG antibody concentration was found in the NPC patients in different N,M or clinical stages( P >0. 05). But in comparison among T stages,it was found that T3 rise by a certain trend and the difference between T3 and T2 groups was statistically significant( P = 0. 048). Conclusions EBV-BRLF1 was highly expressed in NPC tumor tissues; Quantitative EBV-Rta / IgG antibody kits can be used as a clinical indicator of early screening for NPC;The expression of EBV-BRLF1 gene and concentration of serum EBV-Rta / IgG antibody were not associated with N,M or clinical stages,but had a certain correlation with the T staging concerning local tissue invasion.更多还原